FDA Inspection 1033975 — Carter BloodCare

Carter BloodCare — FEI 3002603147

The FDA completed an inspection of Carter BloodCare on December 6, 2017 in Bedford, TX. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
December 6, 2017
Fiscal Year
2018
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Bedford, TX (United States)

Citations

IDCFRDescription
22421 CFR 640.4(f)Arm preparation
37721 CFR 640.120(a)Notification to and approval from CBER
7821 CFR 606.100(c)Record review prior to release
9821 CFR 606.100(c)Thorough investigations